STOCKSCOUTER

StockScouter Premium

StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance

ARPO AERPIO PHARMACEUTICALS StockScouter® Report

3

StockScouter® Score

AERPIO PHARMACEUTICALS, a micro cap value company in the healthcare sector, is expected to slightly underperform the market over the next six months with higher than average risk

10 is the best possible rating. Learn more.

Summary

Positives

  • The enterprise value-to-sales ratio is much lower than the average for comparably-sized companies in the StockScouter universe. Very Positive

 

Concerns

  • Earnings growth in the past year has decelerated rapidly compared to earnings growth in the past three years. Negative
  • The multi-period measure of relative price change and consistency is well below average. Negative
  • The 50-day moving average for ARPO is significantly below its 200-day moving average. Negative

 

Short-term Outlook

Over the next 1-2 months, StockScouter forecasts that micro cap stocks will be in favor, value stocks will be neutral, and healthcare stocks will be in favor.

Expected Risk/Return

Progress: 100% done.
Progress: 40% done.
Low
High

Core Model Grades

D
C
A
F

Previous Ratings

3
4
3